Aligos Therapeutics, Inc. Net Fee Amt
Aligos Therapeutics, Inc. (ALGS) had Net Fee Amt of $252.72 as of 2026-08-04, per its S-8 filed 2026-08-06.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-06
- 2026-08-04: Net Fee Amt $252.72.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $252.72 S-8 · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |